X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (15) 15
clinical neurology (10) 10
index medicus (9) 9
middle aged (9) 9
parkinson's disease (8) 8
aged (7) 7
female (7) 7
male (7) 7
parkinson disease - physiopathology (7) 7
levodopa (6) 6
adult (5) 5
levodopa - therapeutic use (5) 5
neurology (5) 5
neurosciences (5) 5
parkinson disease - drug therapy (5) 5
severity of illness index (4) 4
aged, 80 and over (3) 3
antiparkinson agents - therapeutic use (3) 3
apoptosis (3) 3
dyskinesia (3) 3
motor fluctuations (3) 3
neurons (3) 3
parkinsons-disease (3) 3
animals (2) 2
antipsychotic agents - therapeutic use (2) 2
clinical medicine (2) 2
cohort studies (2) 2
depression (2) 2
disorders (2) 2
dopa (2) 2
dopamine (2) 2
dopamine agonists - therapeutic use (2) 2
europe (2) 2
israel (2) 2
klinisk medicin (2) 2
levodopa - adverse effects (2) 2
magnetic resonance imaging (2) 2
medical and health sciences (2) 2
medicin och hälsovetenskap (2) 2
medicine & public health (2) 2
multiple system atrophy (2) 2
multiple system atrophy - physiopathology (2) 2
nervous system diseases (2) 2
neurologi (2) 2
neuroprotective agents - therapeutic use (2) 2
orthopedics (2) 2
parkinson disease - complications (2) 2
parkinson disease - diagnosis (2) 2
parkinson disease - genetics (2) 2
parkinson disease - pathology (2) 2
parkinson disease - psychology (2) 2
parkinson disease - therapy (2) 2
patient (2) 2
pharmacology & pharmacy (2) 2
pharmacology/toxicology (2) 2
prospective studies (2) 2
psychiatry (2) 2
radioactive tracers (2) 2
receptors, dopamine - physiology (2) 2
safety (2) 2
single-nucleotide polymorphism (2) 2
surveys and questionnaires (2) 2
tomography, emission-computed, single-photon (2) 2
treatment outcome (2) 2
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine - pharmacology (1) 1
6-month (1) 1
administration, inhalation (1) 1
age factors (1) 1
agonists (1) 1
analysis (1) 1
anesthesiology (1) 1
animal diseases (1) 1
antagonist (1) 1
antioxidants - therapeutic use (1) 1
antiparkinson agents - adverse effects (1) 1
antiparkinsonian agents (1) 1
antipsychotic agents - adverse effects (1) 1
antipsychotic drugs (1) 1
antipsychotic-induced parkinsonism (1) 1
anxiety - epidemiology (1) 1
apolipoprotein-e gene (1) 1
articles (1) 1
ataxia - complications (1) 1
ataxia - therapy (1) 1
atrophy (1) 1
autonomic dysfunction (1) 1
autonomic nervous system diseases - diagnosis (1) 1
autonomic nervous system diseases - mortality (1) 1
autonomic nervous system diseases - physiopathology (1) 1
basal ganglia (1) 1
base sequence (1) 1
bcl-2-associated x protein (1) 1
biological sciences (1) 1
biological transport (1) 1
biomedicine (1) 1
brain cancer (1) 1
brain metastases (1) 1
brain neoplasms - diagnostic imaging (1) 1
brain neoplasms - pathology (1) 1
brain neoplasms - radiotherapy (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Neurology, The, ISSN 1474-4422, 2013, Volume 12, Issue 3, pp. 264 - 274
Journal Article
Journal Article
Journal Article
Neurobiology of Aging, ISSN 0197-4580, 2016, Volume 46, pp. 236.e1 - 236.e6
Abstract We have previously reported the whole genome genotyping analysis of two consanguineous siblings clinically diagnosed with early onset Alzheimer’s... 
Neurology | Internal Medicine | Early onset Alzheimer’s disease | CTSF | Kufs disease | Recessive | Homozygosity | Exome sequencing
Journal Article
Psychopharmacology, ISSN 0033-3158, 4/2012, Volume 220, Issue 3, pp. 519 - 528
Antipsychotic-induced parkinsonism (AIP) is a severe adverse affect of antipsychotic drug treatment. Recently, our group performed a genome-wide association... 
Antipsychotic-induced parkinsonism | Neurosciences | Biomedicine | FOG2 | Schizophrenia | Pharmacology/Toxicology | ZFPM2 | Psychiatry | Severity of Illness Index | Genome-Wide Association Study | Cross-Sectional Studies | United States | Antipsychotic Agents - adverse effects | Humans | Middle Aged | Tomography, Emission-Computed, Single-Photon | Logistic Models | Male | Substantia Nigra - metabolism | Transcription Factors - genetics | DNA-Binding Proteins - genetics | Parkinson Disease - physiopathology | Corpus Striatum - metabolism | Jews | Antipsychotic Agents - therapeutic use | Parkinson Disease, Secondary - physiopathology | Adult | Female | Polymorphism, Single Nucleotide | Israel | Parkinson Disease, Secondary - chemically induced | Schizophrenia - drug therapy | GATA FACTORS | FUNCTIONAL POLYMORPHISM | PSYCHIATRY | RS4606 SNP | NEUROSCIENCES | INDUCED MOVEMENT-DISORDERS | INDUCED EXTRAPYRAMIDAL REACTIONS | DISEASE | GENOME-WIDE | PHARMACOLOGY & PHARMACY | DRUG-INDUCED PARKINSONISM | RGS2 GENE | TARDIVE-DYSKINESIA | Care and treatment | Parkinson's disease | Antipsychotic drugs | Genes | Genomics | Physicians (General practice) | Psychotropic drugs | Psychopharmacology | Parkinsons disease | Neuroimaging | Basal ganglia | Dopamine | Neuroleptics | Mental disorders | Neurodegenerative diseases | Neurons | Central nervous system diseases | Data processing | Population studies | Single-nucleotide polymorphism | Putamen | Zinc finger proteins | Movement disorders
Journal Article
European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, 09/2012, Volume 39, Issue 9, p. 1400
  Early assessment of tumor response to therapy is vital for treatment optimization for the individual cancer patient. Induction of apoptosis is an early and... 
Brain cancer | Tomography | Metastasis | Radiation therapy | Apoptosis
Journal Article
Movement Disorders, ISSN 0885-3185, 06/2006, Volume 21, Issue 6, pp. 809 - 815
Journal Article